A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer

References

• van Putten M, de Vos-Geelen J, Nieuwenhuijzen GAP, et al. Long-term survival improvement in oesophageal cancer in the Netherlands. Eur J Cancer. 2018;94:138–147.
   PubMed Web of Science ®Google Scholar
• Grass GD, Cooper SL, Armeson K, et al. Cervical esophageal cancer: a population-based study. Head Neck. 2015;37(6):808–814.
   PubMed Web of Science ®Google Scholar
• Valmasoni M, Pierobon ES, Zanchettin G, et al. Cervical esophageal cancer treatment strategies: a cohort study appraising the debated role of surgery. Ann Surg Oncol. 2018;25(9):2747–2755.
   PubMed Web of Science ®Google Scholar
• Takebayashi K, Tsubosa Y, Matsuda S, et al. Comparison of curative surgery and definitive chemoradiotherapy as initial treatment for patients with cervical esophageal cancer. Dis Esophagus. 2017:30(2):1–5.
   Web of Science ®Google Scholar
• Cao CN, Luo JW, Gao L, et al. Primary radiotherapy compared with primary surgery in cervical esophageal cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(10):918–926.
   PubMed Web of Science ®Google Scholar
• Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–1627.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Guidelines®. NCCN Guidelines® & Clinical Resources 2018. Esophageal and Esophagogastric Junction Cancers (Version 2.2018) 2018 [updated May 22, 2018]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
   Google Scholar
• Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50–v57.
   PubMed Web of Science ®Google Scholar
• Hoeben A, Polak J, Van De Voorde L, et al. Cervical esophageal cancer: a gap in cancer knowledge. Ann Oncol. 2016;27(9):1664–1674.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–175.
   PubMed Web of Science ®Google Scholar
• Pignon JP, Le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.
   PubMed Web of Science ®Google Scholar
• Strojan P, Vermorken JB, Beitler JJ, et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. Head Neck. 2016;38(S1):E2151–E2158.
   PubMedGoogle Scholar
• Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–1598.
   PubMed Web of Science ®Google Scholar
• Chen Y, Ye J, Zhu Z, et al. Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: a randomized, multicenter, phase III clinical trial. JCO. 2019;37(20):1695–1703.
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof M, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084.
   PubMed Web of Science ®Google Scholar
• Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997 ;337(3):161–167.
   PubMed Web of Science ®Google Scholar
• Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. JCO. 2008;26(7):1086–1092.
   PubMed Web of Science ®Google Scholar
• Lee JL, Park SI, Kim SB, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol. 2004;15(6):947–954.
   PubMed Web of Science ®Google Scholar
• Jeene PM, van Laarhoven HWM, Hulshof M. The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer. Best Practice Res Clin Gastroenterol. 2018;36-37:53–59.
   PubMed Web of Science ®Google Scholar
• Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol. 2014;25(3):638–643.
   PubMed Web of Science ®Google Scholar
• Greene FL, Balch Cm Haller Dg, et al. AJCC Cancer Staging Manual, 6th edn. New York: Springer-Verlag; 2002.
   Google Scholar
• Edge SB. Byrd Dr, Compton CC. The AJCC Cancer Staging Manual. 7th edn. New York: Springer. 2010.
   Google Scholar
• Jeene PM, Versteijne E, van Berge Henegouwen MI, et al. Supraclavicular node disease is not an independent prognostic factor for survival of esophageal cancer patients treated with definitive chemoradiation. Acta Oncologica (Stockholm, Sweden. 2017;56(1):33–38.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), v4.03; 2009 [cited 2010 Jun 14]. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
   Google Scholar
• Biondi-Zoccai G, Romagnoli E, Agostoni P, et al. Are propensity scores really superior to standard multivariable analysis?. Contemp Clin Trials. 2011;32(5):731–740.
   PubMed Web of Science ®Google Scholar
• Burgette L, Griffin BA, McCaffrey D. Propensity scores for multiple treatments: a tutorial for the mnps function in the twang package. 2020. Available from: https://cran.r-project.org/web/packages/twang/vignettes/mnps.pdf
   Google Scholar
• McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Statist Med. 2013;32(19):3388–3414.
   PubMed Web of Science ®Google Scholar
• Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–1174.
   PubMed Web of Science ®Google Scholar
• Conroy T, Galais M-P, Raoul J-L, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. The Lancet Oncol. 2014;15(3):305–314.
   PubMed Web of Science ®Google Scholar
• Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. The Lancet Oncol. 2013;14(7):627–637.
   PubMed Web of Science ®Google Scholar
• Luo HS, Huang HC, Lin LX. Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis. Radiat Oncol. 2019;14(1):178.
   PubMed Web of Science ®Google Scholar
• Hulshof M, Geijsen D, Rozema T, et al. A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study. JCO. 2020;38(4_suppl):281–281. Abstract 281.
   PubMed Web of Science ®Google Scholar
• Huang SH, Lockwood G, Brierley J, et al. Effect of concurrent high-dose cisplatin chemotherapy and conformal radiotherapy on cervical esophageal cancer survival. Int J Radiat Oncol Biol Phys. 2008;71(3):735–740.
   PubMed Web of Science ®Google Scholar
• Zhang P, Xi M, Zhao L, et al. Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2015;116(2):257–261.
   PubMed Web of Science ®Google Scholar
• Herrmann E, Mertineit N, De Bari B, et al. Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study. Radiat Oncol. 2017;12(1):97.
   PubMedGoogle Scholar
• Gkika E, Gauler T, Eberhardt W, et al. Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus. Dis Esophagus. 2014;27(7):678–684.
   PubMed Web of Science ®Google Scholar
• Yamada K, Murakami M, Okamoto Y, et al. Treatment results of radiotherapy for carcinoma of the cervical esophagus. Acta Oncologica (Stockholm, Sweden). 2006;45(8):1120–1125.
   PubMed Web of Science ®Google Scholar
• Uno T, Isobe K, Kawakami H, et al. Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus. Dis Esophagus. 2007;20(1):12–18.
   PubMed Web of Science ®Google Scholar
• Ludmir EB, Palta M, Zhang X, et al. Incidence and prognostic impact of high-risk HPV tumor infection in cervical esophageal carcinoma. J Gastrointest Oncol. 2014;5(6):401–407.
   PubMedGoogle Scholar
• Kim TH, Lee IJ, Kim Jh, et al. High-dose versus standard-dose radiation therapy for cervical esophageal cancer: retrospective single-institution study. Head Neck. 2019;41(1):146–153.
   PubMed Web of Science ®Google Scholar
• De B, Rhome R, Doucette J, et al. Dose escalation of definitive radiation is not associated with improved survival for cervical esophageal cancer: a National Cancer Data Base (NCDB) analysis. Dis Esophagus. 2017;30(4):1–10.
   PubMed Web of Science ®Google Scholar
• Zenda S, Kojima T, Kato K, et al. Multicenter phase 2 study of cisplatin and 5-fluorouracil with concurrent radiation therapy as an organ preservation approach in patients with squamous cell carcinoma of the cervical esophagus. Int J Rad Oncol Biol Phys. 2016;96(5):976–984.
   PubMed Web of Science ®Google Scholar
• Blom RL, Sosef MN, Nap M, et al. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma. Dis Esophagus. 2014;27(4):380–387.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Corden BJ, Jacob J, et al. High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984;100(1):19–24.
   PubMed Web of Science ®Google Scholar
• Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2017;28(11):2901–2905.
   PubMed Web of Science ®Google Scholar